Development of novel monoclonal antibody creation system using AI and single cell technoogy

2022 Fiscal Year Final Research Report

• Project/Area Number: 19H02523
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 27040:Biofunction and bioprocess engineering-related
• Research Institution: Nagoya University
• Principal Investigator: NAKANO Hideo 名古屋大学, 生命農学研究科, 教授 (00237348)
• Co-Investigator(Kenkyū-buntansha): ダムナニョヴィッチ ヤスミナ 名古屋大学, 生命農学研究科, 講師 (00754673) ; 兒島 孝明 名城大学, 農学部, 准教授 (40509080)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: monoclonal antibody / human antibody / rabbit antibody / GPCR / single B cell / epitope mapping / bioinformatics

Outline of Final Research Achievements

We have developed and implemented a technology called Ecobody, which can rapidly synthesize and select monoclonal antibodies (Mab) from a single B cell using a cell-free protein synthesis system. Using technologies such as DNA immunization, we have successfully produced rabbit monoclonal antibodies that recognize membrane proteins, which are difficult to obtain with existing methods like the hybridoma technique. We have also succeeded in establishing detection kit for swine influenza virus and in obtaining anti-SARS-Cov2 human monoclonal antibodies from the blood of COVID-19 patients, and partially characterized their properties. In addition, we have analyzed the relations between the affinity and antibody sequences obtained antibody sequences to make better antibodies. Moreover, using bioinformatics, they have developed a method to determine antibody epitopes quickly and inexpensively.

Free Research Field

生物工学

Academic Significance and Societal Importance of the Research Achievements

我々を病原菌やウイルスから守り、がんや自己免疫疾患とも関係している抗体分子は、医薬や検査薬としても大変有用な分子である。またそのターゲット分子の中でGPCR受容体分子は、生命現象の理解や創薬において重要な分子群である。本研究において、このGPCR受容体に対する抗体分子の画期的な取得方法やそのエピトープ解析方法の開発等に成功しており、バイオテクノロジーだけでなく医学領域研究分野への応用を通じ、人々の健康的生活向上に貢献できる。